GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Peter Lynch Fair Value

China Isotope & Radiation (HKSE:01763) Peter Lynch Fair Value : HK$7.78 (As of May. 10, 2024)


View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, China Isotope & Radiation's PEG is 1. China Isotope & Radiation's 5-Year TTM EBITDA Growth Rate is 7.64. China Isotope & Radiation's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.02. Therefore, the Peter Lynch Fair Value for today is HK$7.78.

As of today (2024-05-10), China Isotope & Radiation's share price is HK$11.00. China Isotope & Radiation's Peter Lynch fair value is HK$7.78. Therefore, China Isotope & Radiation's Price to Peter Lynch Fair Value Ratio for today is 1.41.


The historical rank and industry rank for China Isotope & Radiation's Peter Lynch Fair Value or its related term are showing as below:

HKSE:01763' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.4   Med: 1.78   Max: 3.4
Current: 1.41


During the past 9 years, the highest Price to Peter Lynch Fair Value Ratio of China Isotope & Radiation was 3.40. The lowest was 1.40. And the median was 1.78.


HKSE:01763's Price-to-Peter-Lynch-Fair-Value is ranked better than
60% of 190 companies
in the Medical Devices & Instruments industry
Industry Median: 1.74 vs HKSE:01763: 1.41

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


China Isotope & Radiation Peter Lynch Fair Value Historical Data

The historical data trend for China Isotope & Radiation's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation Peter Lynch Fair Value Chart

China Isotope & Radiation Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only - 7.80 12.02 8.77 7.78

China Isotope & Radiation Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.02 - 8.77 - 7.78

Competitive Comparison of China Isotope & Radiation's Peter Lynch Fair Value

For the Medical Devices subindustry, China Isotope & Radiation's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Isotope & Radiation's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where China Isotope & Radiation's Price-to-Peter-Lynch-Fair-Value falls into.



China Isotope & Radiation Peter Lynch Fair Value Calculation

China Isotope & Radiation's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 7.64 *1.018
=7.78

For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Isotope & Radiation's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.02.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


China Isotope & Radiation  (HKSE:01763) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 7.64 instead of 15 in this case.

China Isotope & Radiation's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=11.00/7.78
=1.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Isotope & Radiation Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


China Isotope & Radiation (HKSE:01763) Business Description

Traded in Other Exchanges
N/A
Address
No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines